We are live on
!
Find out more
Harvard Bioscience
HBIO
HBIO
63 hedge funds and large institutions have $11.7M invested in Harvard Bioscience in 2025 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 20 increasing their positions, 15 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
1,240% more call options, than puts
Call options by funds: $67K | Put options by funds: $5K
75% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 8
60% more capital invested
Capital invested by funds: $7.29M → $11.7M (+$4.39M)
33% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 15
7% more funds holding
Funds holding: 59 → 63 (+4)
0.18% more ownership
Funds ownership: 3.73% → 3.92% (+0.18%)
Holders
63
Holders Change
+4
Holders Change %
+6.78%
% of All Funds
0.77%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
20
Reduced
15
Closed
8
Calls
$67K
Puts
$5K
Net Calls
+$62K
Net Calls Change
+$30K
Top Buyers
| 1 |
CCM
Corsair Capital Management
New York
|
+$598K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$417K |
| 3 |
Two Sigma Advisers
New York
|
+$377K |
| 4 |
Two Sigma Investments
New York
|
+$319K |
| 5 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$243K |
